VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

UV Inactivated SARS-CoV vaccine
Vaccine Information
  • Vaccine Name: UV Inactivated SARS-CoV vaccine
  • Target Pathogen: SARS-CoV
  • Target Disease: Severe Acute Respiratory Syndrome (SARS)
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: whole virus(Iwata-Yoshikawa et al., 2014)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Ultraviolet radiation applied to SARS virus. Vaccine causes eosinophilic immunopathology to SARS while providing protection (Iwata-Yoshikawa et al., 2014)
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Host age: 10 weeks (Iwata-Yoshikawa et al., 2014)
  • Host gender: Female (Iwata-Yoshikawa et al., 2014)
  • Vaccination Protocol: 10 μg UV-V subcutaneously injected in back and reimmunized 6 to 7 weeks later (Iwata-Yoshikawa et al., 2014)
  • Immune Response: Induced neutralizing antibodies, Lymphocyte infiltration, Upregulation of IL-4 and CCL24, CD11b+ cells upregulated genes associated with eosinophil induction (Iwata-Yoshikawa et al., 2014).
  • Side Effects: Eosinophil infiltration present in the lungs (Iwata-Yoshikawa et al., 2014)
  • Challenge Protocol: 10 week old BALB/c mice were vaccinated with 10 μg UV-V and boosted 6 weeks later. Four weeks afterwards, the animals were inoculated in the left nostril with 106.5 TCID50 in 30 μl of F-musX(Iwata-Yoshikawa et al., 2014).
  • Efficacy: Most mice survived challenge after weight loss and respiratory disease (Iwata-Yoshikawa et al., 2014)
References
Iwata-Yoshikawa et al., 2014: Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. Journal of virology. 2014; 88(15); 8597-8614. [PubMed: 24850731].